tbuckley/cabot-search huggingface dataset:
DO MANUAL INJURIES DISABLE PHYSICIANS?
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BELGIUM
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Successful renal revascularization after prolonged nonfunction
Authors: R. N. Gulbrandson
Journal: JAMA (1977)

Surgical teaching has suggested that renal nonfunction of more than a few days' duration usually precludes success of revascularization procedures. The efficacy of delayed renal revascularization in selected cases has been reported. In this case, the intravenous pyelogram, renal scan, and ureteral catheterization verified nonfunction 30 days before surgical correction of essentially complete atheromatous occlusion of the renal artery. Postoperative studies conducted six weeks and 18 months postoperatively showed normal bilateral renal function. Current temporal limitations on attempts to preserve renal tissue may be too stringent. Revascularization of kidneys may be successful after prolonged periods of ischemia. (<i>JAMA</i>238:2522-2523, 1977)
Healthy Children. A Volume Devoted to the Health of the Growing Child.
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BOOK REVIEWS
Authors: JOANNE WOHLGANGER
Journal: JNCI Journal of the National Cancer Institute (1991)

BOOK REVIEWS Triumph: Getting Back to Normal When You Have Cancer Marion Morra , Eve Potts . New York : Avon Books , 1990 , 297 pp. $9.95. JOANNE WOHLGANGER JOANNE WOHLGANGER Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 21, 6 November 1991, Page 1585, https://doi.org/10.1093/jnci/83.21.1585-a Published: 06 November 1991
Urinary Sodium Excretion and Cardiovascular Disease Mortality
Authors: K. Aleksandrova, T. Pischon, C. Weikert
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Therapeutics.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Book Review Osler's Principles and Practice of Medicine . By Henry A. Christian, A.M., M.D., LL.D., Sc.D. (hon.), Hon. F.R.C.P. (hon., Can.). Fifteenth edition. 8°, cloth, 1498 pp. New York: D. Appleton-Century Company, Incorporated, 1944. $9.50.
Journal: New England Journal of Medicine (1944)
New York Psychoanalytic Society and Institute
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Changing the cause of death
Authors: W. A. Knaus
Journal: JAMA (1983)

"Patients don't die of their disease," William Osler once wrote, "they die of the physiologic abnormalities of their disease."<sup>1</sup>Advances in medical care now make it necessary to reexamine Osler's observation. In this issue ofThe Journal(p 1055), Hook and co-workers give us such an opportunity, by indicating that despite sophisticated physiological support in an intensive care unit, mortality rates for pneumococcal bacteremia have not changed since major review of the disease by Austrian and Gold nearly 20 years ago.<sup>7</sup> The article by Hook and colleagues is important for two reasons: (1) it provides an update on a long-recognized disease, and (2) it highlights a widely held misperception of the ability of a new therapy to save lives by correcting physiological abnormalities. What do we know about outcome from pneumococcal bacteremia? As Hook and colleagues point out, older patients, especially those with serious underlying health problems, such
The definition and scope of clinical pharmacology
Authors: R. I. Wang
Journal: JAMA (1980)

CLINICAL pharmacology has grown out of a need to extend the discipline of basic pharmacology into clinical practice. A similar evolution of a clinical science took place when clinical pathology became established as a discipline separate from basic pathology. The progenitors of clinical pathology saw that a new type of specialist in pathology, one with firm roots in clinical medicine, was necessary if the study of pathology was to progress in providing improved patient care. Clinical pathology has been an established and recognized discipline for more than half a century. The growth and development of clinical pharmacology has proceeded much more slowly than that of clinical pathology. The earliest systematic clinical investigations into drugs were carried out by Harry Gold, MD, and his associates about 50 years ago. However, it was not until 1952 that Gold first voiced the need for the establishment of a separate discipline incorporating basic pharmacology
Muscular Dystrophy Group of Great Britain
Authors: Pancras Church, E Olsen, M Turner, E Mcnamara, K Shorten, P Frith, P Ward, D Duchesne, G Anderson, S Bernstein, T Bryant, J Caldwell, M Clark, D Craddock, G Cunningham, J Donald, F Eminson, J Goldman, John Goodhart, P Grob, J Ham, Lilian Harris, R Law, J Mccaldin, J Mcmaster, H Mason, M O'sullivan, J Price, D Ratcliffe, B Reiss, E Robinson, Elizabeth Rose, J Rose, K Scott, Katalin Schopflin, Joan Sutherland, J Walker, W Waters, L_ White, J White, H Young, J Zidell, M Linnett, M Macg, C Waine, R Abraham, N Achar, A Agius-Ferrante, T Akintewe, G Ali, G Al-Rawi, Y Al-Saaty, R Angunawela, L Archer, S Ashraf, J Ayres, A Azzam, I Bandak, Lynn Banna, A Barat, D Bareford, M Barry, E Bateman, P Blake, N Boon, L Borysiewicz, M Brooks, A Brown, I Brown, C Campbell, V Carpy, S Chakrabarti, C Chan, Elizabeth Chang, C Chee, S Cheong, H Chong, F Chong, A Chu, W Chung, Anne Cockcroft, D Collas, C Costalos, S Court, Benvon Cramer, R Cranfield, A Crisp, D Cutting, A Dallev, P Dar, G Davies, D Dawkins, J Deanfield, Dc Silva, P Dhillon, J Dick, P Doogan, P Dryburgh, M Silva, A Dunbar, J Evans, M Farage, J Fasler, A Fenech, K-C Fok, J Foster, R Foulds, G Fowler, A Fraser, Christine Fraser- Moodie, R Galbraith, B Gatee, A Gatrad, M Ghouri, J Gibbs, J Gibson, Juliet Gould, D Graham-Brown, J Green, S Mgrimmer, M Gunawardena, D Gunawardena, I Hamilton, F Hannigan, R Harris, T Hay, J Hay, A Henderson, A Hewazy, J Hewitt, Elaine Hicks, C Higgens, A Hill, S Hillier, J Hobbiss, R Holmes, T Hong, G Hope, C Hui, P Hurst, C Jackson, M Jaffery, Jayaram Rai, D Jaya- Sekera, L Jayasinghe, M Johnson, B Jones, P Jones, R Jones, Lesley Kay, Janice Kohler, Mildred Kulasekaram, P Kunju, A Kuti, L F-M Lai, C Laing, R Lee, S Lee, Alison Leiper, J Leonard, T-C Leung, K Liew, Lorraine Linton, R Livingstone, I Low, J Lowes, A Mackay, M Mcmillan, W Mcnabb, G Madhav, Z Mahdi, A Main, R Mariwalla, Linda Marks, Roseda Marshall, C Martin, M Maskill, A Matheson, Margaret Mathieson, R Matthews, Z Mehdi, R Mehta, W Melia, R Melsom, I Melville, S Mendis, G Miller, P Mistry, Z Mistry, J Morgan, J Moriarty, Margaret Muddiman, M Mukunyandela, S Murdoch, Ruth Murgatroyd, O Narayanan, L Nagrani, M Nasar, V Natarajan, R Newton, A Nicholls, R Nightingale, E Nielesani, R Num, P O'connor, M Okleh, P F B O'regan, M Otterburn, K Palmer, P Payne, M Perkins, J Pickvance, R Poulter, G Powell, M Preston, Margaret Price, R Prior, Ragupathy Renganathan, R Rashid, J Reid, B Renton, I Richardson, P Robson, J Rowley, A Rozkovec, J Russell, P Sainsbury, Marcia Sandler, Elzbieta Sawicka, I Scobie, J Scott, M Seervai, V Sharma, D Shiers, I Short, J Shribman, A Silas, Claire Sillince, G Sing, Singaraveloo Muthusamy, G Skowronski, L Sly, V Sood, R Spiller, V Stanley, N Statham, R Stocks, J Stokes, G Supramaniam, M Q-E-K Talukder, J Taylor, M Taylor, King Tiong, J Tooke, G Van Hazel, R Van Zyl-Smit, P Varma, Katherine Venables, Margaret Wallington, J Walters, C Walton, Janine White, P Wilev, M Wilkinson, R Willicombe, N Wong, J Wyld, M Ziada
Journal: BMJ (1977)
P295 Efficacy and safety of tiotropium/olodaterol in patients with copd by ats category
Journal: Thorax (2016)

AbstractF Maltais reports financial support from Boehringer Ingelheim during the conduct of the study and, outside of the submitted work, financial support from Boehringer Ingelheim and GlaxoSmithKline for attendance at advisory boards, financial support from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca and Novartis for speaking activities, and research support from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Nycomed and Novartis.E Pizzichini has nothing to disclose.L Grönke and F Voß are employees of Boehringer Ingelheim Pharma GmbH & Co. KG.E Derom, outside of the submitted work, reports financial support from Boehringer Ingelheim, Actelion, AstraZeneca and Cipla for consultancy work, financial support from Chiesi, AstraZeneca and CSL Behring for advisory board attendance, and research support from Boehringer Ingelheim and GlaxoSmithKline.
Art and Mind
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Extracellular Calcium Effects on Cell Viability and Thiol Homeostasis
Authors: Donald J. Reed, Gary A. Pascoe, Craig E. Thomas
Journal: Environmental Health Perspectives (1990)

Studies of chemically induced cell injury and death, which have used as model systems freshly isolated rat hepatocytes and hepatocytes in culture, are discussed. An important model uses the omission of Ca2+ from the medium during rat hepatocyte incubations. Ca2+ omission induces an intense oxidative stress within hepatocytes incubated in a 95% O2 + 5% CO2 atmosphere. The relationship of calcium homeostasis to the parameters of oxidative stress is important to understanding the progression from reversible to irreversible injury. In the Ca2+ omission model, the vitamin E (Vit. E) content of hepatocytes is important for the prevention of cell injury. Recent studies with rat hepatocytes show that ruthenium red (RR) and La3+, which block Ca2+ translocation through the mitochondrial uniport, can prevent malondialdehyde (MDA) formation, reduced glutathione (GSH), and protein-SH loss, Vit. E loss, and LDH leakage induced by Ca2+ omission from the incubation medium. Ca2+ omission promoted a marked loss of mitochondrial transmembrane potential (delta phi) that was prevented by RR, EGTA, Vit. E, and desferrioxamine. The absence of extracellular Ca2+ may cause mitochondrial Ca2+ cycling that contributes to the observed oxidative stress, resultant loss of cell viability, and protein thiol homeostasis. Chemical agents including a glutathione-depleting agent, ethacrynic acid, and a redox cycling agent, adriamycin, increase the loss of cell viability caused by a Ca2(+)-free medium, but they have some additional effects on cellular processes. The demise of cell viability by the agent is also preventable by Vit. E supplementation. Ca2+ has a role in cell injury that appears to uniquely involve mitochondrial homeostasis.
Months Instead of Years
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1): A randomized, multidisciplinary, multinational phase III trial.
Authors: Alexander Stein, Dirk Arnold, Wolf O. Bechstein, John A. Bridgewater, David Goldstein, Lars Henrik Jensen, Stefan Kasper, Heinz Josef Klümpen, Volker Kunzmann, Udo Lindig, Ansgar W Lohse, Bjoern Nashan, John Neil Primrose, Rentsch Markus, Jennifer Anne Shannon, Marianne Sinn, Weiss Karl-Heinz, Henning Wege
Journal: Journal of Clinical Oncology (2015)

TPS4140 Background: Despite complete resection, disease free survival (DFS) and overall survival (OS) of patients with cholangiocarcinoma (CCA) or muscle invasive gallbladder carcinoma (GBCA) is poor. Thus, evaluation of adjuvant chemotherapy (CTx) in biliary tract cancer (BTC) in a large randomized trial is warranted. Methods: ACTICCA-1 is a phase III investigator initiated trial (EudraCT No 2012–005078-70). With respect to ABC-02 trial, cisplatin and gemcitabine for 24 weeks were selected as investigational treatment. Based on adjuvant trials in pancreatic cancer with a comparable postoperative recovery time, inclusion of patients within a maximum interval of 16 weeks between surgery and start of CTx was chosen. Due to the different prognosis and treatment susceptibility of gallbladder carcinoma, two separate cohorts for CCA and GBCA were included. Randomization will be stratified for lymph node status for both cohorts and localization for CCA. The primary endpoint is DFS and secondary endpoints include OS, safety, tolerability and quality of life. For CCA, DFS 24 months post surgery (DFSR@24) is expected to be 40% without CTx. CTx should increase DFS@24 to 55% to be regarded as clinically relevant. With a power of 80% and a significance level of 5%, 271 evaluable study patients have to be followed for 24-28 months to observe 166 events. For GBCA, adjuvant CTx should increase DFSR@24 from 35% to 55% to be relevant; thus, 154 evaluable patients and 90 events are needed. In both cohorts, randomization will be 1:1 with adjuvant CTx for 24 weeks and imaging every 12 weeks. The ACTICCA-1 trial has been started in Germany (funded by the Deutsche Krebshilfe and supported by medac) in 2014 and recently in the Netherlands (funded by the Dutch Cancer Society and supported by medac). Furthermore, Australia, Denmark and the United Kingdom (funded by Cancer Research UK) will particpate within the next months. Conclusion: The randomized, multinational, multidisciplinary phase III ACTICCA-1 trial will establish the role of adjuvant gemcitabine and cisplatin in patients with BTC. Clinical trial information: NCT02170090.